REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker, has demonstrated a favourable safety and tolerability profile when given as an adjunctive treatment to patients with major depressive disorder (MDD), and may have a rapid and sustained antidepressant effect vs placebo.
Boys who adhere to a diet rich in animal protein in middle childhood are less likely to externalize problems and become aggressive during adolescence, while adherence to the traditional/starch dietary pattern is associated with attention problems among girls, according to a study in Colombia.
Treatment with 42-mg lumateperone daily leads to significant improvement in depression symptoms, with no serious safety issues, among patients with major depressive episodes associated with both bipolar I and II disorders, a study has shown.
Mindfulness training (MT) delivered through an app (Unwinding Anxiety) significantly alleviates anxiety, a study has shown. Increases in psychological nonreactivity and reductions in worry mediate the effects of this app, which suggests a specific targeting of reinforcement learning.
In individuals who had been on antidepressant therapy for at least 9 months but felt well enough to consider discontinuing, the risk of relapse of depression was greater among those who stopped vs those who carried on with their current regimen, the ANTLER* trial has shown.
In individuals with clinically diagnosed mild-to-moderate Alzheimer’s disease (AD), treatment with the angiotensin II receptor blocker (ARB) losartan for 12 months did not reduce the rate of brain atrophy, findings from the phase II RADAR* trial suggest.